Shanghai Junpaiyingshi Pharmaceutical

Shanghai Junpaiyingshi Pharmaceutical is a clinical-stage biotechnology company based in China, primarily focused on developing innovative small molecule inhibitors for oncology. As a subsidiary of Junshi Biosciences, the company leverages a robust R&D infrastructure to advance its targeted therapy pipeline. Its lead candidate, JPY-1188, is a potent and selective CDK4/6 inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. The company aims to address significant unmet medical needs in cancer treatment by developing next-generation therapies with improved efficacy and safety profiles. Junpaiyingshi operates as a specialized vehicle within the broader Junshi Biosciences ecosystem to accelerate the development of small molecule assets.